nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5...

31

Transcript of nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5...

Page 1: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 2: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 3: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 4: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 5: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 6: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 7: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 8: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 9: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 10: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 11: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 12: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 13: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 14: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 15: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 16: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 17: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 18: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 19: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 20: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 21: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 22: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 23: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 24: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 25: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 26: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 27: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 28: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 29: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 30: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Page 31: nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/5 ...depts.washington.edu/hepstudy/presentations/... · Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007

Phase 3 - depts.washington.edudepts.washington.edu/hepstudy/presentations/uploads/164/ally3.pdf · Hepatitis Source: Nelson DR, et al. Hepatology 2015;61:1127-35. web study Treatment-Experienced

Phase 3 - depts.washington.edudepts.washington.edu/hepstudy/presentations/uploads/164/ally3.pdf · Hepatitis Source: Nelson DR, et al. Hepatology 2015;61:1127-35. web study Treatment-Experienced

ION-4 - University of Washingtondepts.washington.edu/hepstudy/presentations/uploads/149/ion4_ls.pdfION-4 Trial: Features ION-4 Trial Design: Open-label, single group, phase 3 trial,

ION-4 - University of Washingtondepts.washington.edu/hepstudy/presentations/uploads/149/ion4_ls.pdfION-4 Trial: Features ION-4 Trial Design: Open-label, single group, phase 3 trial,

Counseling Patients With Chronic Hepatitis C Virus Infectiondepts.washington.edu/hepstudy/presentations/uploads/26/m...Debika Bhattacharya, MD, MSc Assistant Professor of Medicine

Counseling Patients With Chronic Hepatitis C Virus Infectiondepts.washington.edu/hepstudy/presentations/uploads/26/m...Debika Bhattacharya, MD, MSc Assistant Professor of Medicine

nfs/aesop01/hw00/d44/hepstudy/presentations/uploads/1 ...depts.washington.edu › ... › 1 › test_presentation.pdf · o ute ravr: umma o e tu ies Phase 2a Trial in Treatment Naïve

nfs/aesop01/hw00/d44/hepstudy/presentations/uploads/1 ...depts.washington.edu › ... › 1 › test_presentation.pdf · o ute ravr: umma o e tu ies Phase 2a Trial in Treatment Naïve

nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/41/best of …depts.washington.edu/hepstudy/presentations/uploads/41/... · 2013. 9. 25. · some portal areas Stage 2: Fibrous

nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/41/best of …depts.washington.edu/hepstudy/presentations/uploads/41/... · 2013. 9. 25. · some portal areas Stage 2: Fibrous

Phase 3 - University of Washingtondepts.washington.edu/hepstudy/presentations/... · Abbreviations: DCV = daclatasvir; SOF = sofosbuvir 97 78 100 89 50 92 0 20 40 60 80 100 Treatment

Phase 3 - University of Washingtondepts.washington.edu/hepstudy/presentations/... · Abbreviations: DCV = daclatasvir; SOF = sofosbuvir 97 78 100 89 50 92 0 20 40 60 80 100 Treatment

Treatment of Hepatitis C in Patients with Renal Insufficiencydepts.washington.edu/hepstudy/presentations/... · Hepatitis C Treatment Issues Related to Renal Disease • Hepatitis

Treatment of Hepatitis C in Patients with Renal Insufficiencydepts.washington.edu/hepstudy/presentations/... · Hepatitis C Treatment Issues Related to Renal Disease • Hepatitis

Treatment Naïve - University of Washingtondepts.washington.edu/hepstudy/presentations/uploads/81/...Source: Manns M, et al. Lancet. 2014;384:414-26. Simeprevir + PEG + RBV in Treatment-Naïve

Treatment Naïve - University of Washingtondepts.washington.edu/hepstudy/presentations/uploads/81/...Source: Manns M, et al. Lancet. 2014;384:414-26. Simeprevir + PEG + RBV in Treatment-Naïve

Treatment of HCV in Patients with HIV Coinfectiondepts.washington.edu/hepstudy/presentations/... · HCV/HIV co-infected versus HCV monoinfection (P

Treatment of HCV in Patients with HIV Coinfectiondepts.washington.edu/hepstudy/presentations/... · HCV/HIV co-infected versus HCV monoinfection (P

nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/75/ribavirinduration and dose ...depts.washington.edu/hepstudy/presentations/uploads/75/... · 2014-02-18 · Treatment Duration

nfs/bronfs/uwfs/hw00/d44/hepstudy/presentations/uploads/75/ribavirinduration and dose ...depts.washington.edu/hepstudy/presentations/uploads/75/... · 2014-02-18 · Treatment Duration

Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir Viekira …depts.washington.edu/hepstudy/presentations/uploads/131/...Hepatitis web study Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir

Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir Viekira …depts.washington.edu/hepstudy/presentations/uploads/131/...Hepatitis web study Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir

nfs/bronfs/uwfs/hw00/d99/nwaetc/presentations/uploads/102/nnrti …depts.washington.edu/nwaetc/presentations/uploads/102/... · 2013. 6. 3. · Case #4 A 45-year-old woman presents

nfs/bronfs/uwfs/hw00/d99/nwaetc/presentations/uploads/102/nnrti …depts.washington.edu/nwaetc/presentations/uploads/102/... · 2013. 6. 3. · Case #4 A 45-year-old woman presents

Addressing Psychiatric Issues Prior to HCV Treatmentdepts.washington.edu/hepstudy/presentations/uploads/35/m4_l3... · Raison CL, Broadwell SD, Borisov AS, Manatunga AK, Capuron L,

Addressing Psychiatric Issues Prior to HCV Treatmentdepts.washington.edu/hepstudy/presentations/uploads/35/m4_l3... · Raison CL, Broadwell SD, Borisov AS, Manatunga AK, Capuron L,

Treatment Naïve and Treatment Experienceddepts.washington.edu/hepstudy/presentations/uploads/82/cosmos.pdf · Simeprevir + Sofosbuvir +/- Ribavirin in Genotype 1 COSMOS Trial Phase

Treatment Naïve and Treatment Experienceddepts.washington.edu/hepstudy/presentations/uploads/82/cosmos.pdf · Simeprevir + Sofosbuvir +/- Ribavirin in Genotype 1 COSMOS Trial Phase

Hepatitis C Testing Recommendationsdepts.washington.edu/hepstudy/presentations/... · Source: Rein, DB et al Ann Intern Med 2012:156:263-70. web study HCV Testing of Persons Born

Hepatitis C Testing Recommendationsdepts.washington.edu/hepstudy/presentations/... · Source: Rein, DB et al Ann Intern Med 2012:156:263-70. web study HCV Testing of Persons Born

Treatment of Chronic HCV Genotype 5 or 6depts.washington.edu/hepstudy/presentations/uploads/126/m5_l5... · • Decompensated hepatic disease • Major uncontrolled depressive illness

Treatment of Chronic HCV Genotype 5 or 6depts.washington.edu/hepstudy/presentations/uploads/126/m5_l5... · • Decompensated hepatic disease • Major uncontrolled depressive illness

nfs/bronfs/uwfs/hw00/d99/nwaetc/presentations/uploads/117 ...

nfs/bronfs/uwfs/hw00/d99/nwaetc/presentations/uploads/117 ...

CFOA UwFS Protocol Code of Practice v2

CFOA UwFS Protocol Code of Practice v2

State of the Art Therapy for HCV - University of Washingtondepts.washington.edu/hepstudy/presentations/...• Favorable clinical pharmacology profile - No food effect - No significant

State of the Art Therapy for HCV - University of Washingtondepts.washington.edu/hepstudy/presentations/...• Favorable clinical pharmacology profile - No food effect - No significant

Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1 … › hepstudy › presentations › ...Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 A1444040 Trial

Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1 … › hepstudy › presentations › ...Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 A1444040 Trial